A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth

ConclusionsWe demonstratec-kit mutation-driven KIT auto-dimerisation prior to tyrosine kinase phosphorylation as same as the procedure in ligand-dependent signalling pathway and describe a monoclonal antibody, KITMAb, with strong affinity to the dimerisation domain of KIT that blocks the important step in both the KIT signalling pathways. Further, the results suggest that treatment with KITMAb may be potentially therapeutic in imatinib-resistant GIST.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research